https://www.tipranks.com/news/the-fly/denali-therapeutics-price-target-lowered-to-42-from-50-at-oppenheimer

Oppenheimer analyst Jay Olson lowered the firm’s price target on Denali Therapeutics (DNLI) to $42 from $50 and keeps an Outperform rating on the shares following quarterly results and after hosting CEO Ryan Watts at the firm’s 35th Annual Healthcare Conference. Oppenheimer remains optimistic about the multiple opportunities ahead. Near term, it anticipates imminent filing for DNL310 in Hunter syndrome and suspect a high likelihood for priority review; additional regulatory and clinical updates should further boost investor confidence in the iterability of Denali’s ETV platform as the company is expanding the franchise to address more common diseases. The firm updated its model, lowering the probability of success for DNL343 for ALS while adding DNL126.

Discover the Best Stocks and Maximize Your Portfolio:

See what stocks are receiving Strong Buy ratings from top-rated analysts. Filter, analyze, and streamline your search for investment opportunities with  TipRanks’ Stock Screener.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on DNLI:

Denali Therapeutics: Promising Drug Pipeline and Financial Stability Support Buy Rating Denali Therapeutics price target lowered to $32 from $33 at Wedbush Positive Outlook for Denali Therapeutics: Strategic Progress and Promising Developments Support Buy Rating Denali Therapeutics: Promising ETV Platform and Strategic Advancements Justify Buy Rating Denali Therapeutics price target lowered to $80 from $87 at H.C. Wainwright

View Comments